EA202091629A1 - Гуманизированные и деиммунизированные антитела - Google Patents

Гуманизированные и деиммунизированные антитела

Info

Publication number
EA202091629A1
EA202091629A1 EA202091629A EA202091629A EA202091629A1 EA 202091629 A1 EA202091629 A1 EA 202091629A1 EA 202091629 A EA202091629 A EA 202091629A EA 202091629 A EA202091629 A EA 202091629A EA 202091629 A1 EA202091629 A1 EA 202091629A1
Authority
EA
Eurasian Patent Office
Prior art keywords
present
antibodies
amyloidosis
amyloid
amyloid peptide
Prior art date
Application number
EA202091629A
Other languages
English (en)
Inventor
Енс-Ульрих Рафельд
Стивен Гиллис
Торе Хеттман
Штефан Шиллинг
Мартин Кляйншмидт
Original Assignee
Виворайон Терапьютикс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Виворайон Терапьютикс Аг filed Critical Виворайон Терапьютикс Аг
Publication of EA202091629A1 publication Critical patent/EA202091629A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к гуманизированным и деиммунизированным антителам, которые связываются с эпитопом на N-конце пироглутаматного варианта бета-амилоидного пептида (A N3pE), и к профилактическому и терапевтическому лечению заболеваний и состояний, которые связаны с накоплением и отложением амилоидных пептидов, таких как амилоидоз, являющийся группой нарушений и аномалий, ассоциированных с пироглутаматным вариантом амилоидного пептида, как, например, болезнь Альцгеймера, синдром Дауна, церебральная амилоидная ангиопатия и другие связанные аспекты. Более конкретно, оно относится к применению моноклональных антител по настоящему изобретению для связывания пироглутаматного варианта бета-амилоидного пептида в плазме крови, головном мозге и спинномозговой жидкости для предупреждения накопления или для регрессии отложения A N3pE в пределах головного мозга и в различных тканях на периферии и для уменьшения выраженности амилоидоза. Настоящее изобретение дополнительно относится к диагностическим анализам для проведения диагностики амилоидоза с применением антител по настоящему изобретению.
EA202091629A 2018-01-31 2019-01-29 Гуманизированные и деиммунизированные антитела EA202091629A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18154427.1A EP3521308B1 (en) 2018-01-31 2018-01-31 Humanized and de-immunized antibodies
PCT/EP2019/052100 WO2019149689A1 (en) 2018-01-31 2019-01-29 Humanized and de-immunized antibodies

Publications (1)

Publication Number Publication Date
EA202091629A1 true EA202091629A1 (ru) 2020-09-23

Family

ID=61132161

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091629A EA202091629A1 (ru) 2018-01-31 2019-01-29 Гуманизированные и деиммунизированные антитела

Country Status (14)

Country Link
US (1) US20210032315A1 (ru)
EP (1) EP3521308B1 (ru)
JP (1) JP7337077B2 (ru)
KR (1) KR20200116095A (ru)
CN (1) CN111670196A (ru)
AU (1) AU2019214280A1 (ru)
BR (1) BR112020015194A2 (ru)
CA (1) CA3088606A1 (ru)
EA (1) EA202091629A1 (ru)
IL (1) IL276101A (ru)
MX (1) MX2020007986A (ru)
SG (1) SG11202006378PA (ru)
WO (1) WO2019149689A1 (ru)
ZA (1) ZA202004784B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113957095A (zh) * 2021-10-22 2022-01-21 江苏集萃药康生物科技股份有限公司 一种用于构建阿尔兹海默症动物模型的构建方法及其核酸组合物和应用
WO2024107683A1 (en) * 2022-11-17 2024-05-23 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA ANTIBODIES, DOSES, AND USES THEREOF
WO2024133925A1 (en) 2022-12-22 2024-06-27 Bioarctic Ab Antibody which binds to abetape3

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5981830A (en) 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
JP4996926B2 (ja) 2004-02-05 2012-08-08 プロビオドルグ エージー グルタミニルシクラーゼの新規の阻害剤
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
EP2091945B1 (en) 2006-11-09 2014-01-15 Probiodrug AG Novel inhibitors of glutaminyl cyclase
DK2086960T3 (da) 2006-11-09 2014-06-10 Probiodrug Ag Nye inhibitorer af glutaminylcyclase.
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
US7803810B2 (en) 2007-03-09 2010-09-28 Probiodrug Ag Inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
DK2142515T3 (da) 2007-04-18 2014-06-23 Probiodrug Ag Nitrovinyl-diaminderivater som glutaminyl-cyclase-inhibitorer
WO2008128982A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thioxoquinazolinone derivatives as glutaminyl cyclase inhibitors
US8772508B2 (en) 2007-04-18 2014-07-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US9512082B2 (en) 2007-04-18 2016-12-06 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2160380B1 (en) 2007-04-18 2014-04-02 Probiodrug AG Cyano-guanidine derivatives as glutaminyl cyclase inhibitors
JP5676249B2 (ja) 2007-04-20 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
WO2009034158A2 (en) 2007-09-12 2009-03-19 Probiodrug Ag Transgenic mice
CN102131519B (zh) 2008-07-21 2016-01-13 前体生物药物股份公司 诊断抗体测定
EP2344157B1 (en) 2008-09-04 2016-05-25 Probiodrug AG Novel inhibitors
KR101755737B1 (ko) 2009-09-11 2017-07-07 프로비오드룩 아게 글루타미닐 사이클라제의 억제제로서 헤테로사이클릭 유도체
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
CN105263927B (zh) 2013-03-15 2019-03-15 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂
EA038120B1 (ru) 2015-07-16 2021-07-08 Пробайодраг Аг Гуманизированные антитела к пироглутаматному варианту бета-амилоида
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途

Also Published As

Publication number Publication date
MX2020007986A (es) 2020-09-09
IL276101A (en) 2020-08-31
KR20200116095A (ko) 2020-10-08
EP3521308A1 (en) 2019-08-07
BR112020015194A2 (pt) 2020-12-29
EP3521308C0 (en) 2024-03-13
JP7337077B2 (ja) 2023-09-01
CN111670196A (zh) 2020-09-15
CA3088606A1 (en) 2019-08-08
US20210032315A1 (en) 2021-02-04
JP2021512100A (ja) 2021-05-13
AU2019214280A1 (en) 2020-07-23
ZA202004784B (en) 2021-09-29
SG11202006378PA (en) 2020-08-28
WO2019149689A1 (en) 2019-08-08
EP3521308B1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
EA201890313A1 (ru) Гуманизированные антитела к пироглутаматному варианту бета-амилоида
AU2018255221B2 (en) Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
EA202091629A1 (ru) Гуманизированные и деиммунизированные антитела
WO2007068412A3 (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties
MX2009013503A (es) Anticuerpo monoclonal anti-amiloide-beta.
NO20090156L (no) Humanisert antistoff
JP2017113004A5 (ru)
WO2008060364A3 (en) Humani zed antibody against amyloid beta
MX2009013505A (es) Anticuerpos humanizados para amiloide beta.
JP2019529336A (ja) 過リン酸化タウに特異的な抗体およびその使用方法
EP2650308A3 (en) Use of anti-amyloid beta antibody in ocular diseases
EP2586795A3 (en) Use of anti-amyloid beta antibody in ocular diseases
JP2014502141A5 (ru)
RU2017103446A (ru) УЛУЧШЕННЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Аβ-ПРОТОФИБРИЛЛЫ
US11377487B2 (en) Factor H potentiating antibodies and uses thereof
UA102368C2 (ru) СПЕЦИФИЧЕСКИЕ В ОТНОШЕНИИ β-АМИЛОИДА 1-42 МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ ИМЕЮТ ТЕРАПЕВТИЧЕСКИЕ СВОЙСТВА
MX2022006676A (es) Nuevas moleculas para terapia y diagnostico.
PH12012501882A1 (en) Humanized antibody against amyloid beta
RU2013130002A (ru) Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками
JP2014502276A5 (ru)
EA202193058A1 (ru) БИСПЕЦИФИЧЕСКОЕ АНТИТЕЛО К -syn/IGF1R И ЕГО ПРИМЕНЕНИЕ
KR20170058922A (ko) 인자 h 강화 항체 및 그의 용도
RU2011128702A (ru) Средства для лечения пузырчатки, содержащие антитела против лиганда fas
CL2018002690A1 (es) Variantes del anticuerpo humanizado ban2401 que se une específicamente a protofibrillas con una vida media serica aumentada composiciones farmacéuticas y usos en el tratamiento del alzheimer y otras enfermedades neurodegenerativas (divisional de la solicitud n° 53-2017).
EA202090961A1 (ru) Антитела к -синуклеину и их применения